Fluoropharma
Company News
FluoroPharma Obtains US Patent for Imaging Cardiovascular Plaque using FDG
January 26, 2009
FluoroPharma, Inc. announced today that the United States Patent and Trademark Office issued U.S. Patent No. 7,438,891, cover...
Read More...
FluoroPharma, Inc. to Report Preclinical Data on Alzheimer’s Disease and Prostate Cancer PET Imaging Agents
September 8, 2008
FluoroPharma, Inc. announced today that Dr. David Elmaleh, FluoroPharma’s founder and Chief Scientific Advisor, will re...
Read More...
Positive Phase I Safety Results for BFPET
July 23, 2008
FluoroPharma Inc., a company developing breakthrough molecular imaging agents for the Positron Emission Tomography (PET) mark...
Read More...
 Fluoropharma
Products
Products in Clinical and Preclinical Development:
CardioPET (Completed Phase I)

Assessment of cardiac metabolism

  • Identify patients that will benefit from PCI or revascularization and guide intervention
  • Evaluate coronary artery disease (CAD) in patients that cannot exercise
BFPET (Completed Phase I)

Myocardial perfusion imaging in combination with stress testing in patients with presumptive coronary artery disease (CAD)

VasoPET (Preclinical)
  • Evaluation of patients with Acute Coronary Syndrome (ACS)
  • Evaluation of therapy following acute cardiac event or stroke
AZPET (Discovery)

Multiple biomarkers for imaging and treatment of Alzheimer's disease
Fluoropharma